Pharma Mar, S.A. (PHM.MC)
EUR 76.95
(0.59%)
EUR 76.95
(0.59%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 43.36 Million EUR | 1.73% |
| 2022 | 42.63 Million EUR | -13.59% |
| 2021 | 49.33 Million EUR | -12.94% |
| 2020 | 56.66 Million EUR | -34.2% |
| 2019 | 86.11 Million EUR | -7.8% |
| 2018 | 93.4 Million EUR | -6.6% |
| 2017 | 100 Million EUR | 4.73% |
| 2016 | 95.48 Million EUR | 2.02% |
| 2015 | 93.6 Million EUR | 2.33% |
| 2014 | 91.46 Million EUR | -2.97% |
| 2013 | 94.26 Million EUR | -19.26% |
| 2012 | 116.75 Million EUR | -13.99% |
| 2011 | 135.74 Million EUR | -8.4% |
| 2010 | 148.19 Million EUR | 0.0% |
| 2009 | - EUR | 0.0% |
| 2008 | - EUR | -100.0% |
| 2007 | 21.62 Million EUR | -46.88% |
| 2006 | 40.71 Million EUR | 62.89% |
| 2005 | 24.99 Million EUR | -10.46% |
| 2004 | 27.91 Million EUR | -66.92% |
| 2003 | 84.4 Million EUR | 94.12% |
| 2002 | 43.47 Million EUR | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q1 | 40.26 Million EUR | -7.17% |
| 2024 Q3 | 35.84 Million EUR | -2.3% |
| 2024 Q2 | 39.38 Million EUR | -2.18% |
| 2023 Q4 | 43.36 Million EUR | -0.48% |
| 2023 Q2 | 43.67 Million EUR | 0.67% |
| 2023 Q1 | 43.38 Million EUR | 1.78% |
| 2023 FY | 43.36 Million EUR | 1.73% |
| 2023 Q3 | 43.57 Million EUR | -0.23% |
| 2022 Q2 | 44.62 Million EUR | -6.45% |
| 2022 Q4 | 42.63 Million EUR | 0.5% |
| 2022 FY | 42.63 Million EUR | -13.59% |
| 2022 Q1 | 47.69 Million EUR | -3.32% |
| 2022 Q3 | 42.41 Million EUR | -4.94% |
| 2021 Q4 | 49.33 Million EUR | -9.49% |
| 2021 FY | 49.33 Million EUR | -12.94% |
| 2021 Q1 | 54.38 Million EUR | -4.02% |
| 2021 Q2 | 57.23 Million EUR | 5.23% |
| 2021 Q3 | 54.5 Million EUR | -4.76% |
| 2020 Q2 | 62.84 Million EUR | -1.25% |
| 2020 Q1 | 63.63 Million EUR | -26.11% |
| 2020 FY | 56.66 Million EUR | -34.2% |
| 2020 Q4 | 56.66 Million EUR | -5.99% |
| 2020 Q3 | 60.27 Million EUR | -4.09% |
| 2019 Q4 | 86.11 Million EUR | -3.6% |
| 2019 Q1 | 98.57 Million EUR | 5.54% |
| 2019 Q2 | 93.13 Million EUR | -5.51% |
| 2019 Q3 | 89.32 Million EUR | -4.09% |
| 2019 FY | 86.11 Million EUR | -7.8% |
| 2018 Q4 | 93.4 Million EUR | -5.36% |
| 2018 FY | 93.4 Million EUR | -6.6% |
| 2018 Q1 | 101.31 Million EUR | 1.32% |
| 2018 Q2 | 109.86 Million EUR | 8.43% |
| 2018 Q3 | 98.7 Million EUR | -10.16% |
| 2017 Q4 | 100 Million EUR | 1.08% |
| 2017 FY | 100 Million EUR | 4.73% |
| 2017 Q3 | 98.93 Million EUR | -4.63% |
| 2017 Q2 | 103.73 Million EUR | 9.59% |
| 2017 Q1 | 94.65 Million EUR | -0.87% |
| 2016 Q1 | 105.16 Million EUR | 12.35% |
| 2016 Q4 | 95.48 Million EUR | -4.66% |
| 2016 FY | 95.48 Million EUR | 2.02% |
| 2016 Q2 | 107.89 Million EUR | 2.6% |
| 2016 Q3 | 100.15 Million EUR | -7.18% |
| 2015 Q2 | 93.57 Million EUR | 4.61% |
| 2015 Q1 | 89.44 Million EUR | -2.21% |
| 2015 FY | 93.6 Million EUR | 2.33% |
| 2015 Q3 | 109.7 Million EUR | 17.25% |
| 2015 Q4 | 93.6 Million EUR | -14.68% |
| 2014 FY | 91.46 Million EUR | -2.97% |
| 2014 Q4 | 91.46 Million EUR | -4.11% |
| 2014 Q3 | 95.38 Million EUR | -3.45% |
| 2014 Q2 | 98.79 Million EUR | 8.03% |
| 2014 Q1 | 91.45 Million EUR | -2.99% |
| 2013 Q2 | 104.6 Million EUR | -8.41% |
| 2013 FY | 94.26 Million EUR | -19.26% |
| 2013 Q3 | 101.8 Million EUR | -2.68% |
| 2013 Q4 | 94.26 Million EUR | -7.4% |
| 2013 Q1 | 114.2 Million EUR | -2.18% |
| 2012 Q2 | 126.83 Million EUR | -5.64% |
| 2012 Q1 | 134.41 Million EUR | -0.98% |
| 2012 Q3 | 123.55 Million EUR | -2.58% |
| 2012 FY | 116.75 Million EUR | -13.99% |
| 2012 Q4 | 116.75 Million EUR | -5.51% |
| 2011 Q4 | 135.74 Million EUR | 56.12% |
| 2011 FY | 135.74 Million EUR | -8.4% |
| 2011 Q1 | 138.63 Million EUR | -6.45% |
| 2011 Q2 | 142.17 Million EUR | 2.55% |
| 2011 Q3 | 86.94 Million EUR | -38.84% |
| 2010 FY | 148.19 Million EUR | 0.0% |
| 2010 Q1 | 132.64 Million EUR | 0.0% |
| 2010 Q2 | 146.49 Million EUR | 10.45% |
| 2010 Q3 | 149.37 Million EUR | 1.96% |
| 2010 Q4 | 148.19 Million EUR | -0.78% |
| 2009 Q4 | - EUR | 0.0% |
| 2009 FY | - EUR | 0.0% |
| 2009 Q1 | - EUR | 0.0% |
| 2009 Q3 | - EUR | -100.0% |
| 2009 Q2 | 124.14 Million EUR | 0.0% |
| 2008 Q4 | - EUR | 0.0% |
| 2008 FY | - EUR | -100.0% |
| 2007 FY | 21.62 Million EUR | -46.88% |
| 2006 FY | 40.71 Million EUR | 62.89% |
| 2005 FY | 24.99 Million EUR | -10.46% |
| 2004 FY | 27.91 Million EUR | -66.92% |
| 2003 FY | 84.4 Million EUR | 94.12% |
| 2002 FY | 43.47 Million EUR | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Atrys Health, S.A. | 254 Million EUR | 82.926% |
| Biotechnologies Assets SA | 7.12 Million EUR | -508.607% |
| Laboratorios Farmaceuticos Rovi, S.A. | 65.42 Million EUR | 33.715% |